NovaBridge Biosciences (NBP)
NASDAQ
$1.44−$0.0100 (−0.69%) on the dayAs of the close; data may be delayed.
NBP price, last 12 months
Key stats
- Previous close
- $1.45
- Open
- $1.49
- Day range
- $1.32 – $1.49
- 52-week range
- $1.32 – $5.19
- Volume
- 6.4M
- Avg volume (20 days)
- 595.7K
- Market cap
- $159.6M
Performance
1W−10.0%
1M−23.0%
3M−12.2%
6M−43.5%
YTD−63.8%
1Y—
Technicals and fundamentals
About NovaBridge Biosciences
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
- Listed on
- NASDAQ
- Market cap
- $159.6M